Megaphone icon ETF Database is now VettaFi. Read More >
ETFdb Logo
ETFdb Logo
  • ETF Database
  • Channels
    • Active ETF
    • Alternatives
    • Beyond Basic Beta
    • China Insights
    • Climate Insights
    • Commodities
    • Core Strategies
    • Crypto
    • Disruptive Technology
    • Dividend
    • Dual Impact
    • Emerging Markets
    • Energy Infrastructure
    • Entrepreneur ETF
    • Equity ETF
    • ESG
    • ETF Building Blocks
    • ETF Education
    • ETF Strategist
    • Fixed Income
    • Future ETFs
    • Gold & Silver Investing
    • Innovative ETFs
    • Institutional Income Strategies
    • Leveraged & Inverse
    • Managed Futures
    • Modern Alpha
    • Multi-Asset
    • Multi-Factor
    • Nasdaq Investment Intelligence
    • Portfolio Strategies
    • Retirement Income
    • Smart Beta
    • Thematic Investing
    • Volatility Resource
  • Tools
    • ETF Screener
    • ETF Country Exposure Tool
    • ETF Sector Tracker Tool
    • ETF Database Categories
    • Head-To-Head ETF Comparison Tool
    • ETF Stock Exposure Tool
    • ETF Issuer Fund Flows
    • Indexes
    • Mutual Fund To ETF Converter
    • ETF Data for Journalists
    • ETF Nerds
  • Research
    • First Bitcoin ETF
    • ETF Education
    • Equity Investing
    • Dividend ETFs
    • Leveraged ETFs
    • Inverse ETFs
    • Top ETF Sectors
    • Top ETF Issuers
    • Top ETF Industries
  • Webcasts
  • Themes
    • AI ETFs
    • Blockchain ETFs
    • See all Thematic Investing ETF themes
    • ESG Investing
    • Marijuana ETFs
  • Videos & Podcasts
    • ETF 360 Video Series
    • ETF Trends on Videos
    • ETF Trends on Podcasts
    • ETF Prime Podcast
  • PRO
    • Pro Content
    • Pro Tools
    • Advanced
    • FAQ
    • Pricing
    • Free Sign Up
    • Login
  1. Beyond Basic Beta Channel
  2. Evolving Regulatory Environment Could Bolster Biotech
Beyond Basic Beta Channel
Share

Evolving Regulatory Environment Could Bolster Biotech

Tom LydonJul 01, 2021
2021-07-01

The Food & Drug Administration’s (FDA) recent green light of Biogen’s Alzheimer’s disease drug Aducanumab – the first new Alzheimer’s approval in roughly two decades – could be a sign the FDA is taking a new approach to approvals.

That could benefit biotechnology stocks and exchange traded funds, including the VanEck Vectors Biotech ETF (BBH B-). Up over 24% over the past year, BBH has a track record of being positively correlated to swift FDA approvals. The fund was boosted last year when the FDA fast-tracked Moderna’s (NASDAQ: MRNA) COVID-19 vaccine.

Today, the $574.4 million BBH allocates over 8% of its combined weight to Moderna and Biogen (NASDAQ: BIIB), according to issuer data.

The approval of Biogen’s Alzheimer’s treatment, which will be marketed as Aduhelm, “suggests a more constructive regulatory environment for new and upcoming drug approvals, which may provide a better environment for biotech stocks and stock returns,” according to VanEck research.

BBH 1 Year Performance

More BBH Benefits

BBH, which turns 10 years old later this year, is one of the more established biotechnology ETFs on the market, but it’s not a carbon copy of its comparably aged biotech ETF brethren. The VanEck fund tracks the MVIS US Listed Biotech 25 Index, which differs from competing biotech benchmarks. As such, BBH won’t perform in lockstep with rival large cap biotech ETFs.

“Different index methodologies may lead to different holdings, characteristics, and performance, even when choosing from companies in the same industry,” adds VanEck.

Dating back to late last year, BBH’s underlying index benefited from exposure to Biogen, Moderna, and BioNTech – stocks that weren’t as prominently displayed in competing benchmarks. Indeed, BBH does things differently, and it’s often to investors’ benefit.

While the fund shares an overlap by weight of 54% with the largest biotechnology ETF, according to ETF Research Center data, BBH is up 74.8% over the past three years as compared to the 53.3% gain for its larger rival. Interestingly, BBH also sports lower annualized volatility over that period, and its maximum drawdown during that time was 330 basis points less than that of its counterpart.

BBH’s basket is tethered to what could be a more fast-acting FDA.

“BBH focuses on some of the most liquid pure play companies in the industry based on market cap and trading volume. For investors looking to participate in the Biotech revolution, BBH provides diversified exposure to the industry without forcing investors to try pick individual winners,” concludes VanEck.

For more news and information, visit the Beyond Basic Beta Channel.


Content continues below advertisement

Loading Articles...
Help & Info
  • Contact Us
  • Mission Statement
  • Press
Tools
  • ETF Screener
  • ETF Analyzer
  • Mutual Fund to ETF Converter
  • Head-To-Head ETF Comparison
  • ETF Country Exposure Tool
  • ETF Stock Exposure Tool
  • ETF Performance Visualizer
  • ETF Database Model Portfolios
  • ETF Database Realtime Ratings
  • ETF Database Pro
More Tools
  • ETF Launch Center
  • Financial Advisor & RIA Center
  • ETF Database RSS Feed
Explore ETFs
  • ETF News
  • ETF Picks of the Month
  • ETF Category Reports
  • Premium Articles
  • Alphabetical Listing of ETFs
  • Best ETFs
  • Browse ETFs by ETF Database Category
  • Browse ETFs by Index
  • Browse ETFs by Issuer
  • Compare ETFs
Legal
  • Terms of Use and Privacy Policy
  • © ETF Flows LLC
Follow ETF Database
Follow ETF Database

Advertisement

Is Your Portfolio Positioned With Enough Global Exposure?

ETF Education Channel

How to Allocate Commodities in Portfolios

Tom LydonApr 26, 2022
2022-04-26

A long-running debate in asset allocation circles is how much of a portfolio an investor should...

Core Strategies Channel

Why ETFs Experience Limit Up/Down Protections

Karrie GordonMay 13, 2022
2022-05-13

In a digital age where information moves in milliseconds and millions of participants can transact...

}
X